Lacrimal Gland Extranodal Marginal Zone B-cell Lymphoma of MALT-type

Shu Ching Kao, Hui Chuan Kau, Chieh Chih Tsai, Shyh Haw Tsay, Ching Fen Yang, Juin Sen Wu, Wen-Ming Hsu

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Purpose: To evaluate the clinical features and outcome of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type (MALT lymphoma) in the lacrimal gland. Design: Retrospective, noncomparative, observational case series in an academic referral setting. Methods: A consecutive series of 13 histologically verified MALT lymphoma in the lacrimal gland at presentation was studied. Clinical characteristics, treatment, and prognosis were analyzed. Results: Eight males and five females with a median age of 64 years and a median follow-up time of 48 months were included. All patients had no prior lymphoma and initially presented as MALT lymphoma in the lacrimal gland. Extraorbital involvement at diagnosis was noted in six patients (46.2%). Two patients had autoimmune disease, and both had Stage IV disease at presentation. Treatment consisted of surgical resection in one patient, radiotherapy in four, chemotherapy in four, and combined radiotherapy and chemotherapy in four. Complete remissions were obtained in eight patients (61.5%). Patients with bilateral disease (61.5%) had a higher rate of advanced-stage disease and a poor outcome. Recurrence was noted in two patients. At the last follow-up, eight patients were free of disease, three were alive with disease, one died of sepsis as a complication of chemotherapy, and one died of lymphoma. Conclusions: MALT lymphoma in the lacrimal gland has a high rate of extraorbital involvement and synchronous bilateral lacrimal gland involvement at presentation. The prognosis is relatively poor, especially in patients with advanced disease and bilateral involvement. Extensive staging and long-term follow-up are warranted for these patients.

Original languageEnglish
JournalAmerican Journal of Ophthalmology
Volume143
Issue number2
DOIs
Publication statusPublished - Feb 1 2007
Externally publishedYes

Fingerprint

Lacrimal Apparatus
Marginal Zone B-Cell Lymphoma
Drug Therapy
Lymphoma
Radiotherapy
Autoimmune Diseases
Sepsis
Referral and Consultation
Recurrence

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Lacrimal Gland Extranodal Marginal Zone B-cell Lymphoma of MALT-type. / Kao, Shu Ching; Kau, Hui Chuan; Tsai, Chieh Chih; Tsay, Shyh Haw; Yang, Ching Fen; Wu, Juin Sen; Hsu, Wen-Ming.

In: American Journal of Ophthalmology, Vol. 143, No. 2, 01.02.2007.

Research output: Contribution to journalArticle

Kao, Shu Ching ; Kau, Hui Chuan ; Tsai, Chieh Chih ; Tsay, Shyh Haw ; Yang, Ching Fen ; Wu, Juin Sen ; Hsu, Wen-Ming. / Lacrimal Gland Extranodal Marginal Zone B-cell Lymphoma of MALT-type. In: American Journal of Ophthalmology. 2007 ; Vol. 143, No. 2.
@article{42902d7fb6654c528084d3c3f253f02b,
title = "Lacrimal Gland Extranodal Marginal Zone B-cell Lymphoma of MALT-type",
abstract = "Purpose: To evaluate the clinical features and outcome of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type (MALT lymphoma) in the lacrimal gland. Design: Retrospective, noncomparative, observational case series in an academic referral setting. Methods: A consecutive series of 13 histologically verified MALT lymphoma in the lacrimal gland at presentation was studied. Clinical characteristics, treatment, and prognosis were analyzed. Results: Eight males and five females with a median age of 64 years and a median follow-up time of 48 months were included. All patients had no prior lymphoma and initially presented as MALT lymphoma in the lacrimal gland. Extraorbital involvement at diagnosis was noted in six patients (46.2{\%}). Two patients had autoimmune disease, and both had Stage IV disease at presentation. Treatment consisted of surgical resection in one patient, radiotherapy in four, chemotherapy in four, and combined radiotherapy and chemotherapy in four. Complete remissions were obtained in eight patients (61.5{\%}). Patients with bilateral disease (61.5{\%}) had a higher rate of advanced-stage disease and a poor outcome. Recurrence was noted in two patients. At the last follow-up, eight patients were free of disease, three were alive with disease, one died of sepsis as a complication of chemotherapy, and one died of lymphoma. Conclusions: MALT lymphoma in the lacrimal gland has a high rate of extraorbital involvement and synchronous bilateral lacrimal gland involvement at presentation. The prognosis is relatively poor, especially in patients with advanced disease and bilateral involvement. Extensive staging and long-term follow-up are warranted for these patients.",
author = "Kao, {Shu Ching} and Kau, {Hui Chuan} and Tsai, {Chieh Chih} and Tsay, {Shyh Haw} and Yang, {Ching Fen} and Wu, {Juin Sen} and Wen-Ming Hsu",
year = "2007",
month = "2",
day = "1",
doi = "10.1016/j.ajo.2006.10.044",
language = "English",
volume = "143",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Lacrimal Gland Extranodal Marginal Zone B-cell Lymphoma of MALT-type

AU - Kao, Shu Ching

AU - Kau, Hui Chuan

AU - Tsai, Chieh Chih

AU - Tsay, Shyh Haw

AU - Yang, Ching Fen

AU - Wu, Juin Sen

AU - Hsu, Wen-Ming

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Purpose: To evaluate the clinical features and outcome of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type (MALT lymphoma) in the lacrimal gland. Design: Retrospective, noncomparative, observational case series in an academic referral setting. Methods: A consecutive series of 13 histologically verified MALT lymphoma in the lacrimal gland at presentation was studied. Clinical characteristics, treatment, and prognosis were analyzed. Results: Eight males and five females with a median age of 64 years and a median follow-up time of 48 months were included. All patients had no prior lymphoma and initially presented as MALT lymphoma in the lacrimal gland. Extraorbital involvement at diagnosis was noted in six patients (46.2%). Two patients had autoimmune disease, and both had Stage IV disease at presentation. Treatment consisted of surgical resection in one patient, radiotherapy in four, chemotherapy in four, and combined radiotherapy and chemotherapy in four. Complete remissions were obtained in eight patients (61.5%). Patients with bilateral disease (61.5%) had a higher rate of advanced-stage disease and a poor outcome. Recurrence was noted in two patients. At the last follow-up, eight patients were free of disease, three were alive with disease, one died of sepsis as a complication of chemotherapy, and one died of lymphoma. Conclusions: MALT lymphoma in the lacrimal gland has a high rate of extraorbital involvement and synchronous bilateral lacrimal gland involvement at presentation. The prognosis is relatively poor, especially in patients with advanced disease and bilateral involvement. Extensive staging and long-term follow-up are warranted for these patients.

AB - Purpose: To evaluate the clinical features and outcome of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type (MALT lymphoma) in the lacrimal gland. Design: Retrospective, noncomparative, observational case series in an academic referral setting. Methods: A consecutive series of 13 histologically verified MALT lymphoma in the lacrimal gland at presentation was studied. Clinical characteristics, treatment, and prognosis were analyzed. Results: Eight males and five females with a median age of 64 years and a median follow-up time of 48 months were included. All patients had no prior lymphoma and initially presented as MALT lymphoma in the lacrimal gland. Extraorbital involvement at diagnosis was noted in six patients (46.2%). Two patients had autoimmune disease, and both had Stage IV disease at presentation. Treatment consisted of surgical resection in one patient, radiotherapy in four, chemotherapy in four, and combined radiotherapy and chemotherapy in four. Complete remissions were obtained in eight patients (61.5%). Patients with bilateral disease (61.5%) had a higher rate of advanced-stage disease and a poor outcome. Recurrence was noted in two patients. At the last follow-up, eight patients were free of disease, three were alive with disease, one died of sepsis as a complication of chemotherapy, and one died of lymphoma. Conclusions: MALT lymphoma in the lacrimal gland has a high rate of extraorbital involvement and synchronous bilateral lacrimal gland involvement at presentation. The prognosis is relatively poor, especially in patients with advanced disease and bilateral involvement. Extensive staging and long-term follow-up are warranted for these patients.

UR - http://www.scopus.com/inward/record.url?scp=33846430860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846430860&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2006.10.044

DO - 10.1016/j.ajo.2006.10.044

M3 - Article

VL - 143

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 2

ER -